Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes with funds managed...
view press release
September 16, 2019, 08:00 AM
|
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, has closed up to $50 million in secured debt financing from an investment fund managed by Pharmakon Advisors and $12 million in an extension on its Series B preferred stock....
view press release
July 28, 2014, 08:33 AM
|